Zevra Therapeutics (ZVRA) Files Preliminary Proxy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Zevra Therapeutics (ZVRA) Files Preliminary Proxy

Zevra Therapeutics Files Preliminary Proxy

March 31, 2025 4:12 PM EDT

Confirms Receipt of Two Director Nominees from Daniel J. Mangless

Stockholders Are Not Required to Take Action at This Time

CELEBRATION, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq:GS ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies to people living with rare disease, today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) in connection with the Companys 2025 Annual Meeting of Stockholders (Annual Meeting). Stockholders do not need to take any action with respect to the 2025 Annual... More